PT3142641T - Formulações para o tratamento de hipertiroidismo - Google Patents

Formulações para o tratamento de hipertiroidismo

Info

Publication number
PT3142641T
PT3142641T PT157345570T PT15734557T PT3142641T PT 3142641 T PT3142641 T PT 3142641T PT 157345570 T PT157345570 T PT 157345570T PT 15734557 T PT15734557 T PT 15734557T PT 3142641 T PT3142641 T PT 3142641T
Authority
PT
Portugal
Prior art keywords
hyperthyroidism
formulations
treatment
Prior art date
Application number
PT157345570T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Dendropharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendropharm Gmbh filed Critical Dendropharm Gmbh
Publication of PT3142641T publication Critical patent/PT3142641T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT157345570T 2014-05-13 2015-05-12 Formulações para o tratamento de hipertiroidismo PT3142641T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102014106749 2014-05-13

Publications (1)

Publication Number Publication Date
PT3142641T true PT3142641T (pt) 2021-03-02

Family

ID=53524526

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157345570T PT3142641T (pt) 2014-05-13 2015-05-12 Formulações para o tratamento de hipertiroidismo

Country Status (9)

Country Link
US (1) US10369135B2 (zh)
EP (1) EP3142641B1 (zh)
CN (1) CN106714794B (zh)
CA (1) CA2975163C (zh)
DE (1) DE112015002229A5 (zh)
ES (1) ES2856324T3 (zh)
PL (1) PL3142641T3 (zh)
PT (1) PT3142641T (zh)
WO (1) WO2015172769A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016102198A1 (de) 2016-02-09 2017-08-24 Dendropharm Gmbh Multidosierapplikator für halbfeste galenische Zubereitungen
CN111264385B (zh) * 2020-03-10 2021-12-24 华中农业大学 一种单倍体诱导剂及其使用方法
TWI723802B (zh) * 2020-03-12 2021-04-01 矽品精密工業股份有限公司 電子封裝件及其製法
EP4134073A1 (en) 2021-08-11 2023-02-15 HM HerbaMedica GmbH Pharmaceutical compositions comprising dendritic nanocarriers and cannabis active agents
EP4417198A1 (en) 2023-02-14 2024-08-21 MYOB GmbH in Gründung Pharmaceutical compositions comprising a psychedelic drug and a dendritic nanocarrier

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046089C (zh) 1993-07-24 1999-11-03 陈凌 外敷用抗甲状腺乳膏
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
DE10143962A1 (de) * 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE102004039875A1 (de) 2004-08-17 2006-03-09 Universität Dortmund Nanotransportsystem mit dendritischer Architektur
CN100406063C (zh) * 2005-05-18 2008-07-30 陈凌 外敷用抗甲状腺软膏及其制备方法
US8124128B2 (en) * 2005-11-08 2012-02-28 Industrial Technology Research Institute Amphiphilic block copolymers and nano particles comprising the same
DE102006034026A1 (de) 2006-07-17 2008-01-24 Beiersdorf Ag Kosmetischer Stift
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
CA2788736C (en) 2010-02-03 2020-03-31 Mivenion Gmbh Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis
WO2012051416A1 (en) * 2010-10-13 2012-04-19 Shape Pharmaceuticals, Inc. Pharmaceutical formulation for histone deacetylase inhibitors
CN102631312A (zh) * 2011-02-09 2012-08-15 张蔚 外敷用复方抗甲状腺凝胶剂及其制备方法
EP2923695A1 (en) 2014-03-25 2015-09-30 DendroPharm GmbH Hyperbranched polyglycerol sulfates with hydrophobic cores

Also Published As

Publication number Publication date
DE112015002229A5 (de) 2017-06-29
EP3142641A2 (de) 2017-03-22
US20170143675A1 (en) 2017-05-25
PL3142641T3 (pl) 2021-08-23
EP3142641B1 (de) 2020-11-25
CN106714794A (zh) 2017-05-24
WO2015172769A3 (de) 2016-01-14
CA2975163A1 (en) 2015-11-19
ES2856324T3 (es) 2021-09-27
CN106714794B (zh) 2021-05-11
US10369135B2 (en) 2019-08-06
CA2975163C (en) 2023-09-19
WO2015172769A2 (de) 2015-11-19

Similar Documents

Publication Publication Date Title
IL280485A (en) Sustained-release pridopidine preparations
HK1232147A1 (zh) 用於治療纖維化的賽尼克韋羅
HK1258062A1 (zh) 給予惡拉戈利的方法
HK1232137A1 (zh) 治療化合物和組合物
IL252062A0 (en) Transdermal compositions
GB201415569D0 (en) Therapeutic Compounds
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
ZA201606075B (en) Pharmaceutical compositions of sitagliptin
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
PT3122349T (pt) Composições para o tratamento da autodigestão
GB201416832D0 (en) Methods of treatment
PL3142641T3 (pl) Preparaty do leczenia nadczynności tarczycy
PL3184492T3 (pl) Preparat antyseptyczny
ZA201700518B (en) Use of active compound compositions
GB201416273D0 (en) Therapeutic compounds
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
GB201412010D0 (en) Treatment of hypertransaminasemia
IL253125A0 (en) Preparations based on tetracaine for use as an anesthetic
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment
GB201418500D0 (en) Therapeutic compositions
GB201418299D0 (en) Therapeutic compositions